Dalteparin: Pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic diseases

European Journal of Medical Research

Volumn 9, Issue 4, 2004, Pages 215-224

  Pineo, Graham F ^a   Hull, Russell D ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Acute anticoagulation; Deep vein thrombosis; Low molecular weight heparin (LMWH); Prophylaxis; Pulmonary embolism; Unfractionated heparin (UFH); Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

BLOOD CLOTTING; CORONARY ARTERY DISEASE; DRUG EFFECT; HUMAN; MOLECULAR WEIGHT; NEOPLASM; REVIEW; SURGERY; THROMBOEMBOLISM;

ANTICOAGULANTS; BLOOD COAGULATION; CORONARY DISEASE; DALTEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MOLECULAR WEIGHT; NEOPLASMS; SURGICAL PROCEDURES, OPERATIVE; THROMBOEMBOLISM;

EID: 3242663648     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Dunn CJ, Jarvis B. Dalteparin an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease. Drugs 2000; 60 (1): 203-237
2. Dunn CJ, Sorkin EM. Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. Drugs 1996; 52 (2): 276-305
3. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119 (1 Suppl): 64S-94S
4. Lane DA, Denton J, Flynn AM, Thunberg L, Lindahl U. Anticoagulant activities of heparin oligasaccharides and their neutralization by platelet factor 4. Biochem J 1984; 218 (3): 725-732
5. Holmer E, Söderberg K, Bergqvist D, Lindahl U. Heparin and its low molecular weight derivatives: anticoagulant and antithrombotic properties. Haemostasis 1986; 16 (Suppl 2): 1-7
6. Padilla A, Gray E, Pepper DS, Barrowcliffe TW. Inhibition of thrombin generation by heparin and low molecular weight (LMW) beparins in the absence and presence of platelet factor 4 (PF4). Br J Haematol 1992; 82 (2): 406-413
7. Marmur JD, Anand SX, Bagga RS, et al. The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration. JACC 2003; 41(3): 394-402
8. Collet JP, Montalescot G, Lison L, Choussat R, et al. Percutaneous coronary intervention after subcutaneous enoxaparin pre-treatment in patients with unstable angina pectoris. Circulation 2001; 103 (5): 658- 63
9. Millet J, Thevenaiux J, Tachon G, et al. The antithrombotic potential of dalteparin in man assessed indirectly by Wessler's technique. Thromb Haemost 1996; 76 (6): 989-992
10. Nagge J, Crowther M, Hirsh J. Is impaired renal function a contraindication to the use of low-molecular- weight heparin? Arch Intern Med 2002; 162: 2605- 2609
11. McDonald E, Landry F, Rabbat C, et al. Relationship between peak anti-Xa levels and calculated creatinine clearance in ICU patients receiving low molecular weight heparin. Critical Care 2003; 7(Suppl 2): P112
12. Eriksson BI, Soderberg K, Widlund L, Wandeli B, Tengborn L, Risberg B. A comparative study of three low-molecular-weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers. Thromb Haemost 1995; 73: 398-401
13. Bergqvist D, Burmark US, Frisell J, et al. Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications. Haemostasis 1986; 16 (Suppl 2): 11-18
14. Collignon F, Frydman A, Caplain H, et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins - dalteparin, enoxaparin and nadroparin - administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 1995; 73 (4): 630-640
15. Bratt G, Törnebohm E, Widlund L, Lockner D. Low molecular weight heparin (Kabi 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res 1986; 42 (5): 613-620
16. Simonneau G, Bergmann JF, Kher A, Soria C, Tobelem G. Pharmacokinetics of a low molecular weight heparin [Fragmin] in young and elderly subjects. Thromb Res 1996; 66 (5): 603-607
17. Jørgensen B, Nielsen C, Rasmussen LH. Erythrocyte adhesion affects the bioavailability of low-molecular- weight heparin [Abstract]. Haemostasis 1998; 28 (Suppl 3): 134
18. Palm M, Mattsson C. Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance. Thromb Haemost 1987; 58 (3): 932-935
19. Andrassy K, Eschenfelder V. Are the pharmacokinetic parameters of low molecular weight heparins predictive of their clinical efficacy? Thromb Res 1996; 81 (Suppl 2): S29-S38
20. Toss H, Wallentin L, Siegbahn A, et al. Influences of sex and smoking habits on anticoagulation activity in low-molecular-weight heparin treatment of unstable coronary artery disease. Am Heart J 1999; 137 (1): 72-78
21. Yee JYV, Duffull SB. The effect of body weight on dalteparin pharmacokinetics - A preliminary study. Eur J Clin Pharmacol 2000; 56: 293-297
22. Wilson SJ, Wilbur K, Burton E. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism. Haemostasis 2001; 31 (1): 42-48
23. Crowther MA, Berry LR, Monagle PT, et al. Mechanisms responsible for the failure of protamine to inactive low-molecular-weight heparin. Br J Haemat 2002; 116: 178-186
24. Pineo GF, Hull RD. Dalteparin sodium. Exp Op Pharmacotherapy 2001; 2 (8): 1325-1337
25. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA Jr et al. Prevention of venous thromboembolism. Chest 2001; 119 (1 Supp): 132S-175S
26. Ockelford PA, Patterson J, Johns AS. A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin). Thromb Haemost 1989; 62 (4): 1046-1049
27. Kakkar VV, Cohen AT, Edmonson RA, et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. Lancet 1993; 341: 259-265
28. Nurmohamed MT, Rosendaal FR, Büller HR, et al. Low molecular weight heparin in the prophylaxis of venous thrombosis: a meta-analysis. Lancet 1992; 340: 152-156
29. Bergqvist D, Burmark US, Frisell J, et al. Thromboprophylactic effect of low molecular weight heparin started in the evening before elective general abdominal surgery: a comparison with low-dose heparin. Semin Thromb Haemost 1990; 16 (Suppl 1): 19-24
30. Bergqvist D, Burmark US, Flordal PA, et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2,500 versus 5,000 Xa units in 2070 patients. Brit J Surg 1995; 82 (4): 496-501
31. Rasmussen MS, Jorgensen LN, Wille-Jorgensen P, et al. Prolonged thromboprophylaxis with low molecular weight heparin (dalteparin) after major abdominal surgery: the FAME study. J Thromb Haemost 2003; 1 Supplement 1 July: abstract #OC399
32. Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002; 346 (13): 975,80
33. Rasmussen MS, Wille-Jorgensen P, Jorgensen LN, et al. Prolonged thromboprophylaxis with low molecular weight heparin (dalteparin) following major abdominal surgery for malignancy. Blood 2003; 102 (11): Abstract #186
34. Agnelli G, Bergqvist D, Cohen A, et al. A randomised double-blind study to compare the efficacy and safety of fondaparinux with dalteparin in the prevention of venous thromboembolism after high-risk abdominal surgery: the Pegasus study. J Thromb Haemost 2003; 1 Supplement 1 July: abstract #OC006
35. Borsted E, Urdal K, Handeland G, Abildgaard U. Comparison of low molecular weight heparin vs. unfractionated heparin in gynaecological surgery. Act Obstetric Gynecol Scand 1992; 71 (6): 471-475
36. Borsted E, Urdal K, Handeland G, et al. Comparison of low molecular weight heparin vs. unfractionated heparin in gynecological surgery. Acta Obstet Gynecol Scand 1992; 71: 471-75
37. Dechavanne M, Ville D, Berruyer M, et al. Randomized trial of a low-molecular-weight heparin (Kabi 2165) versus adjusted-dose subcutaneous standard heparin in the prophylaxis of deep-vein thrombosis after elective hip surgery. Haemost 1989; 19 (1): 5-12
38. Torholm C, Broeng L, Jorgensen PS, et al. Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery. J Bone J Surg 1991; 73 (3): 434-438
39. Francis CW, Pellegrini Jr VD, Totterman S, et al. Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. J Bone J Surg Am 1997; 79 (9): 1365-72
40. Hull RD, Pineo GF, Francis C, et al. Low-molecular- weight heparin prophylaxis using dalteparin in close proximity to surgery vs. warfarin in hip arthroplasty patients. Arch Intern Med 2000; 160 (14): 2199-2207
41. Hull RD, Pineo GF, Stein PD, et al. Timing of initial administration of low molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: A Systematic Review. Arch Intern Med 2001; 161: 1952-1960
42. Andersen BS: Postoperative activation of the haemostatic system - influence of prolonged thromboprophylaxis in patients undergoing total hip arthroplasty. Haemostasis 1997; 27 (5): 219-27
43. White RH, Gettner S, Newman JM, et al. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. N Engl J Med 2000; 343 (3): 1758
44. Colwell CW Jr, Collis DK, Paulsen R, et al. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. J Bone Joint Surg Am 1999; 81 (7): 932-40
45. Bergqvist D, Benoni G, Bjorgell O, et al. Low molecular weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996; 335 (10): 696-700
46. Planes A, Vouchelle N, Darmon JY, Fagola M, Bellaud M, Huet Y. Risk of deep venous thrombosis after hospital discharge in patients having undergone total hip replacement: double blind randomised comparison of enoxaparin versus placebo. Lancet 1996; 348: 224-228
47. Dahl OE, Andreassen G, Aspelin T, et al. Prolonged thromboprophylaxis following hip replacement surgery: results of a double-blind prospective, randomised, placebo-controlled study with dalteparin (Fragmin). Thromb Haemost 1997; 77 (1): 26-31
48. Lassen MR, Borris LC, Andersen BS, et al: Efficacy and safety of prolonged thromboprophylaxis with a low-molecular-weight heparin (dalteparin) after total hip arthroplasty: the Danish prolonged prophylaxis (DaPP) study. Thromb Res 1998; 89 (6): 281-287
49. Hull RD, Pineo GF, Francis C, et al. Low-molecular- weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients. Arch Intern Med 2000; 160 (14): 2208-2215
50. Comp PC, Spiro TE, Friedman RJ, et al. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. J Bone J Surg Am 2001; 83-A (3): 336-345
51. Hull RD, Pineo GF, Stein PD, et al. Extended out-of- hospital low-molecular weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: A Systemic Review. Ann Intern Med 2001; 135 (10): 858-869
52. Eriksson BI, Bergqvist D, Kalebo P, et al. Melagatran for Thrombin inhibition in Orthopaedic surgery. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002; 360: 1441-1447
53. Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. Ann Intern Med 1999; 130: 789-799
54. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992; 326: 975-982
55. Marder VJ, Soulen RL, Atichartakarn V, et al. Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. J Lab Clin Med 1977; 89 (5): 1018-1029
56. Lindmarker P, Holmstrom M, Granqvist S, et al. Comparison of once-daily subcutaneous Fragmin with continuous intravenous unfractionated heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994; 72 (2): 186-190
57. Luomanmaki K, Grankvist S, Hallert C, et al. A multicenter comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. J Intern Med 1996; 240 (2): 85-92
58. Fiessinger JN, Lopez-Fernandez M, Gatterer E, et al. Once-daily subcutaneous dalteparin, a low molecular weight heparin, for the initial treatment of acute deep vein thrombosis. Thromb Haemost 1996; 76 (2): 195-199
59. Meyer G, Brenot F, Pacouret G, et al. Subcutaneous low-molecular-weight heparin Fragmin versus intravenous unfractionated heparin in the treatment of acute non massive pulmonary embolism: an open randomized pilot study. Thromb Haemost 1995; 74 (6): 1432-1435
60. Wells PS, Kovacs MJ, Bormanis J, et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular- weight heparin: a comparison of patient self-injection with homecare injection. Arch Intern Med 1998; 158 (16); 1809-1812
61. Kovacs MJ, Anderson D, Morrow B, et al. Out-patient treatment of pulmonary embolism with dalteparin. Thromb Haemost 2000; 83 (2): 209-211
62. Savage KJ, Wells PS, Schulz V, et al. Outpatient use of low molecular weight heparin (dalteparin) for the treatment of deep vein thrombosis of the upper extremity. Thromb Haemost 1999; 82 (3): 1008-1010
63. Das SK, Cohen AT, Edmonson RA, Melissari E, Kakkar VV. Low-molccular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomised trial. World J Surg 1996; 20 (5): 521-526
64. Lee AYY, Levine MN, Baker RI, et al. Low-molecular- weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349 (2): 146-53
65. Lee AYY, Julian JA, Levine MN, et al. Long-term treatment with dalteparin low-molecular-weight heparin (LMWH) may improved survival in patients with non-metastatic malignancy and venous thromboembolism (VTE). J Thromb Haemost 2003; 1 (Suppl 1); Abstract # OC004
66. Kakkar AK, Kadziola Z, Williamson RCN, et al. Low molecular weight heparin (LMWH) therapy and survival in advanced cancer. Blood 2003; 102 (11): Abstract #557
67. Klerk CPW, Smorenburg SM, Otten JMMB, et al. Malignancy and low molecular weight-heparin therapy: the MALT trial. J Thromb Haemost 2003; 1 (Suppl 1): Abstract #OC195
68. Lensing AWA. Anticoagulation in acute ischaemic stroke: deep vein thrombosis prevention and long- term stroke outcomes. Blood Coagul Fibrinolysis 1999; 10 (Suppl 2): S123-SI27
69. Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular weight heparin versus aspirin in patients with acute ischaemic stroke and arterial fibrillation: a double-blind randomized study. Lancet 2000; 355: 1205-1210
70. Kay R, Wong KS, Yu YL, et al. Low-molecular- weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995; 333 (24): 1588-1593
71. Sandset PM, Dahl T, Stiris M, Rostad B, Scheel B, Abildgaard U. A double-blind and randomized placebo- controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke. Semin Thromb Haemost 1990; 16 (Suppl): 25-33
72. Prins MH, Gelsema R, Sing AK, van Heerde LR, den Ottolander GJ. Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients. Haemost 1989; 19 (5): 245-50
73. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 2001; 119 (Suppl 1): 300S- 320S
74. Leizorovicz A, Cohen AT, Turpie AGG, et al. A randomised placebo controlled trial of dalteparin for the prevention of venous thromboembolism in 3706 acutely III medical patients PREVENT medical thromboprophylaxis study. J Thromb Haemost 2003; 1 (Suppl 1): OC396
75. Edmondson RA, Cohen AT, Das SK, et al. Low-molecular- weight heparin versus aspirin and dipyridamole after femoropopliteal bypass grafting. Lancet 1994; 344: 914-918
76. Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contra- indications to coumarin. Thromb Haemost 1994; 71 (1): 7-11
77. Monreal M, Alastrue A, Rull M, et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices - prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 1996; 75 (2): 251-253
78. Pettilä V, Kaaja R, Leinonen P, et al. Thromboprophylaxis with low molecular weight heparin (Dalteparin) in pregnancy. Thromb Res 1999; 96 (4): 275-282
79. Pettila V, Leinonen P, Markkola A, et al. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 2002; 87 (2): 182-6
80. Jacobsen AF, Qvigstad E, Sandset PM. Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy. Br J Obst Gyn 2003; 110 (2): 139-44